BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22803810)

  • 1. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.
    Lawrence HR; Martin MP; Luo Y; Pireddu R; Yang H; Gevariya H; Ozcan S; Zhu JY; Kendig R; Rodriguez M; Elias R; Cheng JQ; Sebti SM; Schonbrunn E; Lawrence NJ
    J Med Chem; 2012 Sep; 55(17):7392-7416. PubMed ID: 22803810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
    Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
    ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.
    Heron NM; Anderson M; Blowers DP; Breed J; Eden JM; Green S; Hill GB; Johnson T; Jung FH; McMiken HH; Mortlock AA; Pannifer AD; Pauptit RA; Pink J; Roberts NJ; Rowsell S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1320-3. PubMed ID: 16337122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
    Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
    J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
    Kwiatkowski N; Deng X; Wang J; Tan L; Villa F; Santaguida S; Huang HC; Mitchison T; Musacchio A; Gray N
    ACS Chem Biol; 2012 Jan; 7(1):185-96. PubMed ID: 21992004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
    Wang S; Midgley CA; Scaërou F; Grabarek JB; Griffiths G; Jackson W; Kontopidis G; McClue SJ; McInnes C; Meades C; Mezna M; Plater A; Stuart I; Thomas MP; Wood G; Clarke RG; Blake DG; Zheleva DI; Lane DP; Jackson RC; Glover DM; Fischer PM
    J Med Chem; 2010 Jun; 53(11):4367-78. PubMed ID: 20462263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.
    Shaaban MR; Saleh TS; Mayhoub AS; Farag AM
    Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
    Coumar MS; Chu CY; Lin CW; Shiao HY; Ho YL; Reddy R; Lin WH; Chen CH; Peng YH; Leou JS; Lien TW; Huang CT; Fang MY; Wu SH; Wu JS; Chittimalla SK; Song JS; Hsu JT; Wu SY; Liao CC; Chao YS; Hsieh HP
    J Med Chem; 2010 Jul; 53(13):4980-8. PubMed ID: 20550212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.
    Coumar MS; Leou JS; Shukla P; Wu JS; Dixit AK; Lin WH; Chang CY; Lien TW; Tan UK; Chen CH; Hsu JT; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2009 Feb; 52(4):1050-62. PubMed ID: 19140666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Ustilago maydis Aurora kinase as a novel antifungal target.
    Tückmantel S; Greul JN; Janning P; Brockmeyer A; Grütter C; Simard JR; Gutbrod O; Beck ME; Tietjen K; Rauh D; Schreier PH
    ACS Chem Biol; 2011 Sep; 6(9):926-33. PubMed ID: 21671622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors.
    Ando R; Ikegami H; Sakiyama M; Ooike S; Hayashi M; Fujino Y; Abe D; Nakamura H; Mishina T; Kato H; Iwase Y; Tomozane H; Morioka M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4709-11. PubMed ID: 20573509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
    Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
    PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
    Talele TT; McLaughlin ML
    J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3).
    Lum C; Kahl J; Kessler L; Kucharski J; Lundström J; Miller S; Nakanishi H; Pei Y; Pryor K; Roberts E; Sebo L; Sullivan R; Urban J; Wang Z
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3578-81. PubMed ID: 18502127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
    Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
    Shao H; Shi S; Huang S; Hole AJ; Abbas AY; Baumli S; Liu X; Lam F; Foley DW; Fischer PM; Noble M; Endicott JA; Pepper C; Wang S
    J Med Chem; 2013 Feb; 56(3):640-59. PubMed ID: 23301767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of the potent aurora inhibitor MK-0457 (VX-680).
    Bebbington D; Binch H; Charrier JD; Everitt S; Fraysse D; Golec J; Kay D; Knegtel R; Mak C; Mazzei F; Miller A; Mortimore M; O'Donnell M; Patel S; Pierard F; Pinder J; Pollard J; Ramaya S; Robinson D; Rutherford A; Studley J; Westcott J
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3586-92. PubMed ID: 19447622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
    Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
    Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.